Cite

    Kiran Naqvi et al.. “Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemia.” Cancer, vol. 124, no. 13, 2018, pp. 2740–2747. http://access.bl.uk/ark:/81055/vdc_100066531179.0x000060